Metildigoxin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Cardiac arrhythmias, Heart failure
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses. Maintenance: Continue with 50-300 mcg daily by mouth in divided doses.
Elderly: Dose reduction may be required.

Oral
Cardiac arrhythmias, Heart failure
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses.
Elderly: Dose reduction may be required.
Renal Impairment
Dialysis: Initially, 30-50% of the usual dose.
CrClDosage
<50per 1.48 m2: Dose reduction may be needed.
Chống chỉ định
Wolff-Parkinson-White syndrome or other evidence of an accessory pathway; hypertrophic obstructive cardiomyopathy.
Thận trọng
Severe pulmonary disease, hypoxia, myxoedema, acute MI, severe heart failure, acute myocarditis, chronic constrictive pericarditis, acute glomerulonephritis and CHF, idiopathic hypertrophic subaortic stenosis. IV admin in hypertensive patients. Incomplete AV block, especially in those with Adams-Stokes attacks. Increased carotid sinus sensitivity, frequent ventricular premature contractions or ventricular tachycardia. Withhold 1-2 days before elective cardioversion. Electrolyte disturbances, thyroid dysfunction. Elderly, premature infants, renal impairment. Not an appropriate form of therapy for any ventricular arrhythmia. Pregnancy.
Phản ứng phụ
Nausea, vomiting, anorexia, diarrhoea, abdominal pain, headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams, delirium, acute psychoses, hallucinations, convulsions, blurred vision, colour vision may be affected, gynaecomastia.
Potentially Fatal: Heart failure, supraventricular or ventricular arrhythmias, conduction defects.
Quá liều
Symptoms: Nausea, vomiting, anorexia, diarrhoea, abdominal pain, headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams, delirium, acute psychoses, hallucinations, convulsions, blurred vision, colour vision may be affected, gynaecomastia. Management: Acute poisoning: Gastric lavage if patient presents within 1 hr of ingestion. Repeated doses of activated charcoal, colestyramine and colestipol may be given. Haemodialysis or peritoneal dialysis, and forced diuresis with furosemide have generally been ineffective. Antiarrhythmic treatment may be necessary. Correct hypokalaemia and other electrolyte disturbances. Massive poisoning: Reverse progressive hyperkalaemia. Soluble insulin with glucose may be given; if refractory, dialysis may be tried. Massive overdosage has been treated successfully with digoxin-specific antibody fragments.
Tương tác
Increased risk of additive bradycardia with diltiazem. Increased risk of digitalis toxicity with amphotericin B, carbenoxolone, corticosteroids. Increased CV adverse events with HRT. Reduced serum digoxin levels with rifampicin, colestyramine.
Potentially Fatal: Increased digitalis glycosides toxicity with potassium-depleting diuretics. Increased risk of cardiac arrhythmias with IV calcium.
Food Interaction
Many herbal preparations contain cardiac glycosides; additive effects with metildigoxin may possibly occur.
Tác dụng
Description: Metildigoxin is a cardiac glycoside with positive inotropic activity.
Onset: 5-20 min.
Pharmacokinetics:
Absorption: Rapidly and almost completely absorbed from the GI tract.
Metabolism: Hepatic demehylation to digoxin; reduced in patients with cirrhosis.
Excretion: Via urine (about 60% of dose; as unchanged drug and metabolites).
Phân loại MIMS
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Metildigoxin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in